Enimmune Corporation (TPEX:6564)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
17.20
-0.05 (-0.29%)
Mar 10, 2026, 2:07 PM CST
-34.23%
Market Cap 1.24B
Revenue (ttm) 42.23M
Net Income (ttm) -164.74M
Shares Out 72.13M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,160
Average Volume 102,136
Open 17.30
Previous Close 17.25
Day's Range 16.70 - 17.40
52-Week Range 14.65 - 27.10
Beta 0.39
RSI 26.57
Earnings Date Apr 17, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6564
Full Company Profile

Financial Performance

In 2024, Enimmune's revenue was 39.92 million, a decrease of -8.23% compared to the previous year's 43.49 million. Losses were -157.55 million, -29.59% less than in 2023.

Financial Statements

News

There is no news available yet.